Company says it has isolated virus strains for research
Shenzhen Kangtai Biological Products Co has successfully isolated multiple strains of the Delta variant of the coronavirus in a step that could lead to improved vaccines, media reported on Wednesday.
The report by Shenzhen Special Zone Daily quoted a company executive as saying quality requirements for human vaccines will be strictly followed in the evaluation of the isolated strains.
"In response to new challenges in global epidemic prevention and control, Kangtai will fully promote the R&D and industrialization of the vaccine against the coronavirus variant," the executive said, adding that the inactivated COVID-19 vaccine developed by the company and approved for emergency use in China, is still protective and produces a good immune response to a variety of coronavirus variants.
- China strengthens juvenile delinquency prevention and protection against crimes involving minors
- China's CR450 high-speed train moves a step closer to commercial operation
- China to boost rural vitalization and modernization in 15th Five-Year Plan, says minister
- China's procuratorial authorities intensify crackdown on economic and financial crimes in 2025
- China's environmental code: A gift to the future
- China to strengthen legal framework in economic, anti-corruption, and emerging sectors































